Financial Performance - The company's operating revenue for 2024 was CNY 6,168,400,578, representing a decrease of 2.90% compared to CNY 6,352,518,940 in 2023[19]. - The net profit attributable to shareholders increased by 50.87% to CNY 198,751,228 in 2024, compared to CNY 199,594,590 in 2023[19]. - The company's net profit attributable to shareholders decreased to 512,783,647.00 CNY, a decline of 46.62% compared to the previous year[20]. - Operating cash flow increased to 456,344,040.00 CNY, representing a growth of 22.91% year-over-year[20]. - The gross margin for the irradiation processing services improved to 40%, up from 35% in the previous year, due to operational efficiencies[47]. - The company achieved a revenue of 6.168 billion RMB in 2024, with a net profit attributable to shareholders of -362 million RMB[72]. - The company reported a significant increase in revenue, reaching 1.2 billion yuan, representing a 15% year-over-year growth[44]. - The company reported a total revenue of 863.0 million, with a gross profit margin of 27.89%[126]. Business Strategy and Focus - The main business focus has shifted to electronic accelerator research and manufacturing, waste treatment, irradiation processing services, and new material development[17]. - The company is committed to enhancing its nuclear technology applications, particularly in medical health and new materials[17]. - The company is actively involved in various sectors, including material modification, disinfection, environmental governance, and medical technology, indicating a diversified business strategy[42]. - The company is focusing on the modification of materials, particularly in cable materials and heat-shrink materials, with strong demand from the semiconductor and electronic manufacturing sectors[34]. - The company is developing high-performance materials for various applications, including nuclear power and electronic devices, with several projects scheduled for completion in 2024[101]. - The company is focusing on the proton therapy system for cancer treatment, which has been included in the Ministry of Industry and Information Technology's "First Set Catalog (2024 Edition)"[71]. Research and Development - The company has established 14 R&D platforms and holds 270 authorized patents, with 121 R&D personnel, including 11 with postgraduate degrees[54]. - The company has invested 100 million yuan in R&D for new materials, focusing on biodegradable plastics and high-performance polymers[50]. - The company is focusing on the independent and innovative development of proton therapy equipment and key technologies for medical isotope production[64]. - The company filed 12 patents during the reporting period, including 4 inventions, and published 6 papers, contributing to its innovation capabilities[85]. - The company has completed the construction of a new production facility for automotive materials, with an investment of 524.4 million[124]. Market Expansion and Acquisitions - The company is expanding its market presence in Southeast Asia, targeting a 30% market share in the region by 2025[48]. - A strategic acquisition of a local competitor is anticipated to enhance the company's service capabilities and is expected to close by Q3 2024[49]. - The company is actively pursuing market expansion strategies, including potential mergers and acquisitions to enhance its competitive position[125]. - The company plans to expand its market presence through strategic acquisitions and partnerships in the upcoming fiscal year[122]. Operational Efficiency and Cost Management - The company reported a decrease in operational costs by 10% due to improved efficiency measures implemented in 2023[166]. - The company aims to reduce operational costs by 15% through efficiency improvements and technology upgrades[186]. - The company has achieved a production output of 6.299 million tons for polycarbonate materials, reflecting a growth of 5.17% year-over-year[125]. - The company reported a significant increase in production efficiency, with a 13.57% improvement in operational metrics compared to the previous year[125]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[4]. - The company has implemented a comprehensive risk management system and updated its compensation management policies[155]. - The company is addressing risks related to capital support for industrial development and optimizing its asset structure[143]. - The company has established a systematic development strategy for international markets, focusing on key regions such as Asia-Pacific, Europe, Africa, and the Americas[145]. Governance and Management - The company has a complete and independent business structure, not relying on any shareholders or related parties for operations[161]. - The company has established a remuneration and welfare management system that considers operational performance, individual job roles, and work assessments for determining compensation[192]. - The management team emphasized the importance of sustainability initiatives, with a commitment to invest 100 million RMB in green technologies[187]. - The company is focusing on enhancing corporate governance and oversight, as evidenced by the appointment of independent directors with significant industry experience[175][176]. Future Outlook - The company provided guidance for Q1 2024, expecting revenue to be between $1.6 billion and $1.8 billion, reflecting a growth rate of 15% to 20%[166]. - Future strategies include potential market expansion and the development of new technologies in the nuclear sector, aligning with industry trends towards sustainable energy solutions[170][172]. - The company plans to limit the growth of inventory balance to below the growth rate of sales in the new materials sector by 2025[149].

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,061,168,449.85, a decrease of 18.98% compared to ¥1,309,795,211.41 in the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥65,050,648.40, showing a slight improvement of 0.20% from a loss of ¥65,181,223.29 in the previous year[5]. - Net profit for the period was a loss of ¥65,822,026.06, compared to a loss of ¥62,597,662.69 in the previous period, indicating a worsening of approximately 4%[21]. - Total operating revenue decreased to ¥1,061,168,449.85 from ¥1,309,795,211.41, representing a decline of approximately 19% year-over-year[20]. - Total operating costs decreased to ¥1,144,000,244.83 from ¥1,397,561,395.19, a reduction of about 18% year-over-year[20]. Cash Flow - The net cash flow from operating activities improved by 15.92%, amounting to a loss of ¥31,986,734.41 compared to a loss of ¥38,042,141.21 in the same period last year[5]. - Cash flow from operating activities showed a net outflow of ¥31,986,734.41, an improvement from the previous outflow of ¥38,042,141.21[23]. - The cash inflow from operating activities totaled ¥1,286,802,573.45, down from ¥1,494,279,905.78, reflecting a decrease of approximately 14%[23]. - The company reported a 100% decrease in cash received from investment activities, totaling ¥0, as no financial products were invested during the period[11]. - Net cash flow from investing activities was -$80.43 million, compared to -$78.68 million in the previous period[24]. - Cash inflow from financing activities totaled $792.91 million, an increase from $769.28 million year-over-year[24]. - Cash outflow for financing activities was $720.36 million, up from $587.76 million in the prior period[24]. - Net cash flow from financing activities was $72.55 million, down from $181.52 million year-over-year[24]. - The net increase in cash and cash equivalents was -$40.49 million, compared to an increase of $56.62 million in the previous period[24]. - The ending balance of cash and cash equivalents was $1.41 billion, down from $1.08 billion year-over-year[24]. Assets and Liabilities - Total assets at the end of the reporting period were ¥10,531,535,935.17, down 1.60% from ¥10,702,263,483.90 at the end of the previous year[5]. - The total liabilities of the company were CNY 5,047,592,003.11, down from CNY 5,153,939,405.01, representing a decrease of about 2.06%[18]. - Current assets decreased from CNY 6,288,748,438.55 to CNY 6,123,112,485.46, reflecting a decline of approximately 2.63%[17]. - The company's cash and cash equivalents stood at CNY 1,444,595,152.03, down from CNY 1,490,786,138.55, indicating a decrease of about 3.09%[17]. - Accounts receivable decreased from CNY 2,185,366,416.81 to CNY 1,998,990,892.90, a reduction of approximately 8.52%[17]. - Short-term borrowings increased from CNY 1,421,274,006.42 to CNY 1,523,354,808.80, an increase of approximately 7.16%[18]. - The company's equity attributable to shareholders decreased by 1.22%, totaling ¥5,166,300,823.27 compared to ¥5,230,122,212.51 at the end of the previous year[5]. - The company reported a total of 6,123,112,485.46 in current assets, which includes inventory valued at CNY 1,157,707,047.69, an increase from CNY 1,077,521,780.98[17]. - The company has a total of 12,083,642.39 in long-term equity investments, slightly down from 12,271,027.06[17]. Shareholder Information - The company has a significant shareholder, China General Nuclear Power Corporation, holding 28.67% of the shares[15]. Other Financial Metrics - Financial expenses decreased by 51.55% to ¥11,285,475.09, mainly due to increased interest income and exchange gains[10]. - The cash received from tax refunds increased by 80.27% to ¥37,710,701.54, primarily due to an increase in VAT refunds related to medical business[11]. - Research and development expenses decreased to ¥34,383,142.51 from ¥42,425,323.66, a reduction of about 19% year-over-year[20]. - Other comprehensive income after tax increased to ¥1,063,100.31 from ¥158,922.00, showing significant improvement[21]. - The company reported a basic and diluted earnings per share of -0.0688, consistent with the previous period's -0.0689[22]. - The company recorded an investment loss of ¥1,088,206.47, contrasting with a gain of ¥1,879,918.37 in the previous period[20]. Accounting and Reporting - The company has not audited its first-quarter report[25]. - The new accounting standards will be implemented starting in 2025[26].

中广核技（000881）公告，2024年营业收入61.68亿元，同比下降2.90%。归属于上市公司股东的净亏损 3.62亿元，去年同期为净亏损7.37亿元。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

1.会议召开的日期、时间： 证券代码：000881 证券简称：中广核技 公告编号：2025-014 中广核核技术发展股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1.本次股东会未出现否决议案的情形。 2.本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 （1）现场会议召开日期、时间：2025 年 3 月 28 日（星期五）下午 3:30； （2）网络投票日期、时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为：2025 年 3 月 28 日上午 9:15 至 9:25、9:30 至 11:30、下午 1:00 至 3:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年3 月 28 日上午 9:15 至下午 3:00 期间的任意时间。 2.会议召开方式：本次股东会采取现场投票与网络投票相结合的方式。 3.现场会议召开地点：深圳市福田区深南大道 2002 号中广核大厦北楼 19 层 881 会议室。 4.召集人：公司董事会。 5.主 ...

深圳市福田区中心四路 1-1 号 嘉里建设广场第三座第 2803-04 室 邮编：518048 电话：(86-755) 2939-5288 传真：(86-755) 2939-5289 junhesz@junhe.com 北京市君合（深圳）律师事务所 关于中广核核技术发展股份有限公司 2025 年第二次临时股东会的法律意见书 致：中广核核技术发展股份有限公司 北京市君合（深圳）律师事务所（以下简称"本所"）受中广核核技术发展股份 有限公司（以下简称"贵公司"或"公司"）的委托，就贵公司 2025 年第二次临时股东 会（以下简称"本次股东会"）召开的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》、《上市公司股东大会规则》（以下 简称"《股东大会规则》"）等中国现行法律、法规和规范性文件（以下简称"中国法 律、法规"，为本法律意见书之目的，中华人民共和国（以下简称"中国"，包括香 港特别行政区、澳门特别行政区和台湾省，为出具本法律意见书之目的，特指中国 大陆地区）以及现行《中广核核技术发展股份有限公司章程》（以下简称"《公司章 程》"）的有关规定，出具本法律意见书。 本 ...

证券代码：000881 证券简称：中广核技 公告编号：2025-013 中广核核技术发展股份有限公司 关于持股 5%以上股东部分股份被冻结的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 特别风险提示： 1.截至本公告日，中国大连国际经济技术合作集团有限公司（以下简称"国合集团"） 持有本公司 118,914,273 股，占公司总股本的 12.58%，为公司持股 5%以上股东而非控股股 东，亦非公司第一大股东，其所持公司股份被司法冻结不会影响公司的正常生产经营。 2.截至本公告日，国合集团持有公司股份累计被冻结 118,527,046 股，占其所持有的公 司股份的 99.67%，占公司总股本的 12.54%。 中广核核技术发展股份有限公司（以下简称"公司"）于 2025 年 3 月 19 日 接到中国证券登记结算有限责任公司深圳分公司通知及持股 5%以上股东国合集 团函告，获悉国合集团所持有本公司的部分股份被司法再冻结及轮候冻结，具体 事项如下： 一、国合集团持有公司股份被冻结的基本情况 | 股东名 | 是否为 控股股 东或第 一大股 | 本次冻结 | ...

证券代码：000881 证券简称：中广核技 公告编号：2025-012 中广核核技术发展股份有限公司 关于召开 2025 年第二次临时股东会的通知 4.会议召开的日期、时间： （1）现场会议召开日期、时间：2025 年 3 月 28 日（星期五）下午 3:30； （2）网络投票日期、时间：通过深圳证券交易所交易系统进行网络投票的具 体时间为：2025 年 3 月 28 日上午 9:15 至 9:25、9:30 至 11:30、下午 1:00 至 3:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年3 月 28 日上午 9:15 至下午 3:00 期间的任意时间。 5.会议的召开方式：本次股东会采用现场表决与网络投票相结合的方式召开。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、召开会议的基本情况 1.股东会届次：2025年第二次临时股东会。 2.股东会的召集人：公司董事会。 3.会议召开的合法、合规性：公司于2025年3月11日召开的第十届董事会第二 十五次会议审议通过了《关于提请召开2025年第二次临时股东会的议案》，同意公 司 ...

证券代码：000881 证券简称：中广核技 公告编号：2025-011 1.中广核核技术发展股份有限公司（以下简称"公司"）第十届董事会第二 十五次会议（以下简称"本次会议"）通知于 2025 年 3 月 7 日以电子邮件形式 发出。 2.本次会议于 2025 年 3 月 11 日以通讯表决的方式召开。 3.本次会议应出席董事 8 名，实际出席并参与表决董事 8 名。 4.本次会议由公司代行董事长、总经理盛国福先生召集并主持。 5.本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》的规定。 中广核核技术发展股份有限公司 第十届董事会第二十五次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、董事会会议召开情况 于海峰先生不存在《公司法》《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》规定不得提名为董事的情形；未受过中国证监会及 其他有关部门的处罚和证券交易所纪律处分，不存在因涉嫌犯罪被司法机关立案 侦查或者涉嫌违法违规被中国证监会立案稽查尚未有明确结论的情形；除在公司 实际控制人中国广核集团 ...

证券代码：000881 证券简称：中广核技 公告编号：2025-010 2.本次会议于 2025 年 2 月 25 日以通讯表决的方式召开。 3.本次会议应出席董事 8 名，实际出席并参与表决董事 8 名。 4.本次会议由公司半数以上董事推举董事、总经理盛国福先生召集并主持。 5.本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件 和《公司章程》的规定。 中广核核技术发展股份有限公司 第十届董事会第二十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、董事会会议召开情况 1.中广核核技术发展股份有限公司（以下简称"公司"）第十届董事会第二 十四次会议（以下简称"本次会议"）通知于 2025 年 2 月 21 日以电子邮件形式 发出。 为保证公司及董事会正常运作，根据《公司章程》第一百一十九条的规定"董 事长行使的职权包括行使法定代表人的职权"和第一百二十条规定"董事长不能 履行职务或者不履行职务的，由半数以上董事共同推举一名董事履行职务"，经 全体董事共同推举，董事会同意由董事兼总经理盛国福先生代为履行董事长、董 事会战略委 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 中广核核技术发展股份有限公司（以下简称"公司"）为扩大信息披露的覆 盖面，进一步做好投资者关系管理工作，即日起增加《中国证券报》《上海证券 报》为指定信息披露媒体。增加后公司指定信息披露媒体为《中国证券报》《上 海证券报》《证券时报》和巨潮资讯网（http://www.cninfo.com.cn）。 公司所有公开披露的信息均以在《中国证券报》《上海证券报》《证券时报》 和巨潮资讯网（http://www.cninfo.com.cn）上刊登的正式公告为准，敬请广大投 资者理性投资，注意投资风险。 证券代码：000881 证券简称：中广核技 公告编号：2025-009 中广核核技术发展股份有限公司 关于增加指定信息披露媒体的公告 中广核核技术发展股份有限公司 董事会 2025 年 2 月 19 日 特此公告。 ...